All Episodes

Raj Chovatiya, MD, PhD, MSCI: Intravenous vs Subcutaneous GPP Therapy

James Del Rosso, DO: JCAD August 2026 Issue Highlights

Jeffrey Cohen, MD, MPH: Treating Psoriasis in High-Impact Sites

Jason Hawkes, MD, MS: The IL-36 Inflammatory Pathway and Generalized Pustular Psoriasis

James Del Rosso, DO: JCAD July 2026 Issue Highlights

Fabrizio Galimberti, MD, PhD: The Importance of Targeted Therapy for GPP Treatment

James Del Rosso, DO: JCAD June 2026 Issue Highlights

Tina Bhutani, MD, MAS, FAAD: Use of Spesolimab for Generalized Pustular Psoriasis

James Del Rosso, DO: JCAD May 2026 Issue Highlights

Bruce Strober, MD, PhD, FAAD: Providing Care With Risankizumab in Psoriasis

James Del Rosso, DO: JCAD April 2026 Issue Highlights

James Del Rosso, DO, and Joseph Merola, MD, MMSc: What’s New in Cutaneous Lupus Erythematosus

James Del Rosso, DO, Diego Dasilva, MD, and Graham Litchman, DO, MS: Management of Severe Nail Psoriasis and Early Psoriatic Arthritis

James Del Rosso, DO, and David Cotter, MD, PhD: Clinical Management of Conjunctivitis, Erythema, and Arthralgia in AD

James Del Rosso, DO: JCAD March 2026 Issue Highlights

Ted Lain, MD, MBA: Long-Term Results of Deuruxolitinib for Alopecia Areata

James Del Rosso, DO: JCAD February 2026 Issue Highlights

James Del Rosso, DO, and David Cotter, MD, PhD: The Use of Gene-Expression Profile Testing for Effective Atopic Dermatitis Treatment

Amy McMichael, MD: Eight-Week Outcomes With Deuruxolitinib in Alopecia Areata

Graham Litchman, DO, MS: Understanding Long-Term Treatment Success in a Patient With Psoriasis

James Del Rosso, DO: JCAD January 2026 Issue Highlights

Aaron Farberg, MD: Real-World Experiences in Alopecia Areata Treatment

Arash Mostaghimi, MD, MPH, FAAD: Considerations for the Use of Deuruxolitinib in Patients with Alopecia Areata

James Del Rosso, DO: JCAD November 2025 Issue Highlights

Extended-cut Podcast—James Del Rosso, DO, and David G. Cotter, MD, PhD: Targeting the IL-31 Neuroimmune Pathway for Treating Prurigo Nodularis

James Del Rosso, DO: JCAD October 2025 Issue Highlights

David G. Cotter, MD, PhD: The Ideal Patient Candidate for Deuruxolitinib for Patients with Alopecia Areata

David G. Cotter, MD, PhD: Utilizing the 31-gene Expression Profile Test in Patients with Melanoma

David G. Cotter, MD, PhD: Providing Regrowth of Hair in Patients with Alopecia Areata

James Del Rosso, DO: JCAD September 2025 Issue Highlights

James Del Rosso, DO: JCAD August 2025 Issue Highlights

JCAD Dialogues and Reviews: Updates in Photoprotection and Recent Indication Expansions in Psoriasis and Rosacea

James Del Rosso, DO: JCAD June 2025 Issue Highlights

Extended-cut Podcast— Naiem Issa, MD, PhD, and Christopher Bunick, MD, PhD: Mechanisms of Dupilumab-associated Arthralgia in Patients with Atopic Dermatitis

James Del Rosso, DO: JCAD May 2025 Issue Highlights

James Del Rosso, DO: JCAD April 2025 Issue Highlights

James Del Rosso, DO: JCAD February 2025 Issue Highlights

JCAD Dialogues and Reviews: Highlighting a Vitiligo Roundtable Discussion in JCAD

JCAD Dialogues and Reviews: Considerations for Antibiotic Adverse Events

James Del Rosso, DO: JCAD January 2025 Issue Highlights

James Del Rosso, DO: Dermatology Year in Review 2024

JCAD Dialogues and Reviews: Spotlight on a Newly Approved Treatment for Rosacea

James Song, MD: Live from Elevate-Derm West—Why Older Immunosuppressant Agents are Still Relevant in 2024

James Song, MD: Live from Elevate-Derm West—New Topical and Systemic Agents for Atopic Dermatitis

James Del Rosso, DO: New and Exciting Indications for Bimekizumab, Nemolizumab, and Lebrikizumab

James Del Rosso, DO: JCAD October 2024 Issue Highlights

Leon Kircik, MD: Recent IL-17 Inhibitor Approval for Patients with Psoriasis

James Del Rosso, DO: Diagnostic Pearls for Psoriasis

Joel Gelfand, MD, MSCE, FAAD: Managing Cardiovascular Risk in Patients with Psoriasis

James Del Rosso, DO: Consulting Patients with Psoriasis on Biologic Therapy

George Martin, MD: The Utilization of TNF Inhibitors for Psoriasis

James Del Rosso, DO: Identifying Appropriate Patients for TNF inhibitors

Linda Stein Gold, MD: Updates in Systemic Therapies for Psoriasis

George Martin, MD: The Current Role of TNF Inhibitors for Psoriasis

Raj Chovatiya, MD, PhD: Mechanisms of Atopic Dermatitis Therapies

Nicole Keeter, MSHS, PA-C: Incorporating Topical and Oral Treatments into Your Practice

Nicole Keeter, MSHS, PA-C: Focusing on Safety Consideration for the Prescription of JAK Inhibitors

James Del Rosso, DO: Topical Treatment for Atopic Dermatitis

Peter Lio, MD: The Evolution of Topical JAK Inhibitors

James Del Rosso, DO: The Benefits of Topical JAK Inhibitors

Lisa Swanson, MD: Things to Consider When Starting Patients on JAK Inhibitors

Lisa Swanson, MD: Counseling Patients on JAK Inhibitors

Doris Day, MD: The Effect of Stress on Hair Health

Raj Chovatiya, MD, PhD: Discussing Atopic Dermatitis Treatment Risks with Patients

Douglas DiRuggiero, DMSc, PA-C: Safety of JAK Inhibitors for Atopic Dermatitis

Matt Zirwas, MD: Patient Preparatory Guidance for Topical JAK Inhibitors

Douglas DiRuggiero, DMSc, PA-C: An Overview of JAK Inhibitors for Atopic Dermatitis

Matt Zirwas, MD: An Overview of Janus-kinase (JAK) inhibitors for Atopic Dermatitis